HiProMine opens $5.7M share offering to fund its next phase

What's the deal? Polish insect-protein company HiProMineDealroom has a profile for this one. Try Dealroom → has launched a public offering of up to 703,176 Series T shares, aiming to raise about US$5.63M (roughly $5.7 million) if fully subscribed. The shares are priced at US$8 each, with existing shareholders granted pre-emptive rights in a closed subscription.

Why now? The subscription window runs from October 29 to November 20, 2026. The pre-emptive rights will not trade on the NewConnect market and expire after the window closes, so shareholders must act or face dilution.

What's the endgame? Based in Robakowo, HiProMine produces alternative protein and fat ingredients using bioconversion technology for the animal feed and pet food markets. The company says the capital increase will "bolster HiProMine's funding for further development," with an emphasis on scaling production capacity and strengthening its financial base.

The raise marks a notable step-up from its previous round. HiProMine's current market capitalisation stands at US$11.2M.

What could go wrong? The announcement does not disclose how proceeds will be used or demonstrate demand for the shares. The sector backdrop is mixed, with high-profile failures underscoring the risks of building costly capacity ahead of reliable demand.

The signal: European insect-protein firms keep raising capital, increasingly to commercialise existing plants rather than build from scratch — Finland's Volare recently took in €7.1 million and France's Innovafeed secured €51 million. HiProMine's offering is a test of investor appetite for its next phase in a segment where capital is still flowing, but cautiously.

Read more: blog.tipranks.com

Image credit: Generated with Gemini